author-photo

Djibril Liassou

26

Papers

81

Citations

Citation Trend

Filter By

Papers (15) Sort By

Journal Conference Others

Real-World Utilization of Fedratinib for Myelofibrosis Post-Ruxolitinib: Patient Characteristics, Treatment Patterns, and Characterization of Ruxolitinib Failure

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Abstract PS13-37: Effectiveness of eribulin in poor prognosis subgroups of metastatic breast cancer (mBC) patients (elderly, African Americans, and patients with liver metastases) in the United States

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Correction to: Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States.

2021 Advances in Therapy
Show All
- Source
- Cite
- Save
Citations (0)
Lenvatinib and Subsequent Therapy for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Real-World Study of Clinical Effectiveness in the United States.

2020 Advances in Therapy
Show All
- Source
- Cite
- Save
Citations (11)
Real-world outcomes of pembrolizumab plus carboplatin plus paclitaxel or nab-paclitaxel in non-small cell lung cancer (NSCLC).

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
338PReal-world effectiveness of first-line palbociclib + letrozole for metastatic breast cancer 4 years post approval in the US

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Use of a granulocyte colony-stimulating factor for the prevention of febrile neutropenia in the era of value-based care.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Real-world evidence evaluating the use of single versus combination chemotherapy in salvage therapy for metastatic breast cancer.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Real-world evidence evaluating the use of an NK-1 antiemetic in the systemic chemotherapy treatment of metastatic breast cancer.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Observational study of clinical outcomes of eribulin mesylate in metastatic breast cancer after cyclin-dependent kinase 4/6 inhibitor therapy

2019 Future Oncology
Show All
- Source
- Cite
- Save
Citations (7)